Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bexagliflozin vs Sitagliptin in Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
2017-000420-95Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoint: Change in HbA1c from baseline at week 24. Started May 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-000420-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000420-95.